Radient Technologies Announces Conversion of Aurora Cannabis Debenture
EDMONTON and VANCOUVER, July 31, 2017 – Radient Technologies Inc. (“Radient” or the “Corporation”) (TSXV: RTI) and Aurora Cannabis Inc. (“Aurora”) (TSX: ACB) are pleased to announce that the convertible debenture issued to Aurora on February 13, 2017, has been converted into 14,285,714 units of Radient (the “Conversion Units”) pursuant to the acceleration provisions contained therein. Each Conversion Unit consists of one common share and one common share purchase warrant exercisable prior to February 13, 2019 for one additional common share of Radient at an exercise price of $0.33 per warrant.
Radient will also make the final interest payment of $41,096 to Aurora through the issuance of additional 77,540 units to Aurora (the “Interest Units”). Each Interest Unit consists of one common share and one common share purchase warrant exercisable prior to February 13, 2019 for one additional common share of Radient at an exercise price of $0.53 per warrant. The issuance of the Interest Units to Aurora is subject to final approval of the TSX Venture Exchange.
Early Warning Disclosure
Radient has been advised by Aurora that prior to the conversion of the convertible debenture Aurora held 2,777,800 common shares and 2,777,800 purchase warrants. Radient has been further advised by Aurora that after giving effect to the conversion, Aurora holds 17,245,221 common shares and 17,245,221 share purchase warrants of Radient representing approximately 9.6% of the issued and outstanding common shares, and 17.5% of the issued and outstanding common shares on a partially diluted basis.
Aurora acquired the securities for investment purposes. Aurora will evaluate its investment in Radient from time to time and may, based on such evaluation, market conditions and other circumstances, increase or decrease shareholdings as circumstances require through market transactions, private agreements, or otherwise. A copy of the Early Warning report will be filed by Aurora in connection with the acquisition and will be available on Radient’s SEDAR profile. In order to obtain a copy of the early warning report, please contact Nilda Rivera, Aurora’s Controller, at telephone number: 604-362-5207. Aurora’s registered office is located at 1500 – 1199 West Hastings St. Vancouver, British Columbia, V6E 3T5.
About Radient
Radient extracts natural compounds from a range of biological materials using its proprietary MAPTM natural product extraction technology platform which provides superior customer outcomes in terms of ingredient purity, yield, and cost. From its initial 20,000 square foot manufacturing plant in Edmonton, Alberta, Radient serves market leaders in industries that include pharmaceutical, food, beverage, natural health, personal care and biofuel markets. Visit www.radientinc.com for more information.
About Aurora
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal’s West Island. Aurora also recently acquired Pedanios GmbH, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union (“EU”), based in Berlin, Germany. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the only Australian company licensed to conduct research on and cultivate medical cannabis, Aurora’s common shares trade on the TSX under the symbol “ACB”. Visit www.auroramj.com for more information.
Original press release: http://www.newswire.ca/news-releases/radient-technologies-announces-conversion-of-aurora-cannabis-debenture-637629123.html
